Diapin Therapeutics
Contact Us:  (734) 764-9123
  • Home
  • About Us
    • Corporate Overview
    • Corporate Objectives
    • Board of Directors
    • Management Team
    • Scientific Advisory Board
    • Investors
  • News & Media
  • About Type 2 Diabetes
  • Technology Platform
  • Global Diabetes Market
  • Thrombosis
  • Photo Gallery
  • Links to Relevant Sites
  • Contact Us

Corporate Goals and Objectives

Picture

Immediate Objectives
  • Optimize the pharmacodynamics and pharmacokinetics of the peptide
  • Determine a dose-response relationship of DT-109, Byetta, and Onglyza (dipeptidyl peptidase-4 (DPP-4) inhibitor), in a mouse diabetes model, to compare efficacy
  • Determine if DT-109 can differentiate itself from the other compounds in a model of metabolic syndrome (ZSF-1 rats)

Intermediate Goals
  • Complete preclinical development
  • Identify a partner or investor consortium to fund clinical trials for DT-109

Long-term Goal
  • Move DT-109 to global markets by leveraging co-development partnerships with large pharmaceutical companies